array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(14) "ELEKTA LIMITED"
["slug"]=>
string(23) "dbe4b-gb-elekta-limited"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/03cdfb0f-1bfc-426b-afae-aad1f451dee7"
["description"]=>
string(735) "At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in 120 countries and listed on Nasdaq Stockholm. Visit elekta.com to learn more."
["address_street"]=>
string(11) "Linac House"
["address_place"]=>
string(7) "CRAWLEY"
["address_region"]=>
NULL
["founding_date"]=>
string(10) "1996-09-02"
["website_domain"]=>
string(10) "elekta.com"
["website_url"]=>
string(22) "https://www.elekta.com"
["industry_codes"]=>
array(1) {
[0]=>
string(46) "Surgical and Medical Instruments and Apparatus"
}
["employee_count"]=>
int(820)
["article_count"]=>
int(550)
}
["articles"]=>
array(6) {
[0]=>
array(7) {
["title_en"]=>
string(41) "Is Electa (TO:KETA B) A Risky Investment;"
["snippet_en"]=>
string(121) "Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility..."
["url"]=>
string(113) "https://simplywall.st/stocks/se/healthcare/sto-ekta-b/elekta-shares/news/is-elekta-stoekta-b-a-risky-investment-3"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b4f7b639-3420-4d26-837e-ee5e989f1136"
["source"]=>
string(13) "simplywall.st"
["publication_date"]=>
string(10) "2024-03-18"
["categories"]=>
array(2) {
[0]=>
string(19) "Investment Requests"
[1]=>
string(18) "General Investment"
}
}
[1]=>
array(7) {
["title_en"]=>
string(125) "Growing Australia center invests in its radiotherapy future with acquisition of Elekta’s Monaco 5 treatment planning system"
["snippet_en"]=>
string(246) "Queensland 2014-01-02 Private cancer care organization, Oceania Oncology, selects Elekta treatment planning and therapy technology QUEENSLAND, Australia, Jan.3– To match the growth of its radiotherapy treatment capacity in southeast Queensland,"
["url"]=>
string(189) "https://www.elekta.com/press/78be16e0-0329-427c-86b8-0cce20f67b86/growing-australia-center-invests-in-its-radiotherapy-future-with-acquisition-of-elekta-s-monaco-5-treatment-planning-system"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/bda925b7-29b4-4327-bbfa-ede0ec34ce2c"
["source"]=>
string(10) "elekta.com"
["publication_date"]=>
string(10) "2014-01-02"
["categories"]=>
array(2) {
[0]=>
string(11) "Acquisition"
[1]=>
string(18) "General Investment"
}
}
[2]=>
array(7) {
["title_en"]=>
string(51) "Invitation to Investor Day in Crawley, UK, March 12"
["snippet_en"]=>
string(252) "Crawley
2008-01-27
lekta will publish its 9 month report on March 10 at around 13.00 CET followed by a teleconference at 15.00 CET on the same day. On March 12, Elekta will arrange an Investor Day at the company’ s Product Supply Center Oncology"
["url"]=>
string(115) "https://www.elekta.com/press/7fbd1024-831d-4888-95b6-835d2e5d3410/invitation-to-investor-day-in-crawley-uk-march-12"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/23abd462-f0cd-4764-a5e1-b28245d56601"
["source"]=>
string(10) "elekta.com"
["publication_date"]=>
string(10) "2012-03-01"
["categories"]=>
array(1) {
[0]=>
string(18) "General Investment"
}
}
[3]=>
array(7) {
["title_en"]=>
string(62) "ELEKTA ANNOUNCES FIRST LINEAR ACCELERATOR ORDER IN NEW ZEALAND"
["snippet_en"]=>
string(247) "2008-04-24
Elekta, a world leader in clinical solutions for radiosurgery and radiation therapy, has finalized its first-ever New Zealand order. Auckland Radiation Oncology Limited( ARO) have decided to invest in a new Elekta Synergy® system with"
["url"]=>
string(128) "https://www.elekta.com/press/eb52a4af-0daf-42a4-b6de-8c4de380310c/elekta-announces-first-linear-accelerator-order-in-new-zealand"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/c14cfeb7-ea6e-4d02-8e06-4fd571b247cf"
["source"]=>
string(10) "elekta.com"
["publication_date"]=>
string(10) "2008-04-24"
["categories"]=>
array(2) {
[0]=>
string(14) "Product Launch"
[1]=>
string(18) "General Investment"
}
}
[4]=>
array(7) {
["title_en"]=>
string(52) "THE LONDON GAMMA KNIFE CENTRE TO INSTALL LEKSELL …"
["snippet_en"]=>
string(248) "PRESS RELEASE Stockholm, Sweden, February 9, 2007 [Images avaialble for download, please see below.] The London Gamma Knife Centre, which runs in partnership with Barts and The London NHS Trust, has decided to invest in the latest and most advanced"
["url"]=>
string(168) "https://www.elekta.com/pressreleases/93F2905B84D58DD0/the-london-gamma-knife-centre-to-install-leksell-gamma-knife-perfexion-more-patients-to-benefit-from-radiosurgery/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/467c45f7-4f0b-4cb7-a65e-81a7f4fc763a"
["source"]=>
string(10) "elekta.com"
["publication_date"]=>
string(10) "2007-02-09"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(18) "General Investment"
}
}
[5]=>
array(7) {
["title_en"]=>
string(36) "Elekta wins $6m tenders from UK NHS:"
["snippet_en"]=>
string(286) "Benefiting from the UK National Health Service's (NHS) latest wave of investment to improve treatment capacity, Swedish radiotherapy systems developer Elekta has received over $6m worth of orders for six of its Synergy digital linear accelerators from five hospitals across the country."
["url"]=>
string(34) "https://hbw.citeline.com/MT051610/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/d8891bae-12a6-4351-8f4c-f727572dfe24"
["source"]=>
string(12) "citeline.com"
["publication_date"]=>
NULL
["categories"]=>
array(3) {
[0]=>
string(15) "Deals & Tenders"
[1]=>
string(7) "Funding"
[2]=>
string(18) "General Investment"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(35)
}
[1]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(25)
}
[2]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(23)
}
[3]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(19)
}
[4]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(16)
}
[5]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(16)
}
[6]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(15)
}
[7]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(14)
}
[8]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(11)
}
[9]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(11)
}
[10]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(11)
}
[11]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(9)
}
[12]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(8)
}
[13]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(7)
}
[14]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(6)
}
[15]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(6)
}
[16]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(6)
}
[17]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(6)
}
[18]=>
array(2) {
["name"]=>
string(25) "Leadership and Governance"
["count"]=>
int(5)
}
[19]=>
array(2) {
["name"]=>
string(10) "Executives"
["count"]=>
int(5)
}
[20]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(5)
}
[21]=>
array(2) {
["name"]=>
string(21) "Shareholders Feedback"
["count"]=>
int(4)
}
[22]=>
array(2) {
["name"]=>
string(18) "Ecological Impacts"
["count"]=>
int(4)
}
[23]=>
array(2) {
["name"]=>
string(12) "Staff hiring"
["count"]=>
int(4)
}
[24]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(4)
}
[25]=>
array(2) {
["name"]=>
string(17) "Energy Management"
["count"]=>
int(3)
}
[26]=>
array(2) {
["name"]=>
string(20) "Business Development"
["count"]=>
int(3)
}
[27]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(3)
}
[28]=>
array(2) {
["name"]=>
string(20) "Corporate Governance"
["count"]=>
int(2)
}
[29]=>
array(2) {
["name"]=>
string(21) "Intellectual Property"
["count"]=>
int(2)
}
}
}
dbe4b-gb-elekta-limited
ELEKTA LIMITED
Location
Founded
1996-09-02
Website
https://www.elekta.com
Articles
550 Articles
Category
Surgical and Medical Instruments and Apparatus
Description
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in 120 countries and listed on Nasdaq Stockholm. Visit elekta.com to learn more.
Queensland 2014-01-02 Private cancer care organization, Oceania Oncology, selects Elekta treatment planning and therapy technology QUEENSLAND, Australia, Jan.3– To match the growth of its radiotherapy treatment capacity in southeast Queensland,
Crawley
2008-01-27
lekta will publish its 9 month report on March 10 at around 13.00 CET followed by a teleconference at 15.00 CET on the same day. On March 12, Elekta will arrange an Investor Day at the company’ s Product Supply Center Oncology
2008-04-24
Elekta, a world leader in clinical solutions for radiosurgery and radiation therapy, has finalized its first-ever New Zealand order. Auckland Radiation Oncology Limited( ARO) have decided to invest in a new Elekta Synergy® system with
PRESS RELEASE Stockholm, Sweden, February 9, 2007 [Images avaialble for download, please see below.] The London Gamma Knife Centre, which runs in partnership with Barts and The London NHS Trust, has decided to invest in the latest and most advanced
Benefiting from the UK National Health Service's (NHS) latest wave of investment to improve treatment capacity, Swedish radiotherapy systems developer Elekta has received over $6m worth of orders for six of its Synergy digital linear accelerators from five hospitals across the country.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
